Brokerages predict that Leap Therapeutics Inc (NASDAQ:LPTX) will post ($0.42) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Leap Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.35) and the lowest estimate coming in at ($0.48). Leap Therapeutics posted earnings of ($0.73) per share during the same quarter last year, which would indicate a positive year over year growth rate of 42.5%. The firm is scheduled to issue its next quarterly earnings results on Monday, November 12th.

On average, analysts expect that Leap Therapeutics will report full-year earnings of ($2.18) per share for the current financial year, with EPS estimates ranging from ($2.32) to ($1.91). For the next year, analysts forecast that the company will post earnings of ($1.66) per share, with EPS estimates ranging from ($1.81) to ($1.38). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Leap Therapeutics.

Leap Therapeutics (NASDAQ:LPTX) last issued its earnings results on Wednesday, August 8th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.01).

Several brokerages have recently commented on LPTX. ValuEngine upgraded shares of Leap Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 30th. Zacks Investment Research cut shares of Leap Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 22nd.

Shares of NASDAQ:LPTX traded down $0.28 during midday trading on Friday, hitting $6.59. The stock had a trading volume of 164,131 shares, compared to its average volume of 53,067. The stock has a market capitalization of $96.88 million, a PE ratio of -1.99 and a beta of -0.26. Leap Therapeutics has a fifty-two week low of $4.90 and a fifty-two week high of $10.25.

Several institutional investors have recently made changes to their positions in LPTX. Millennium Management LLC bought a new stake in shares of Leap Therapeutics during the 1st quarter valued at approximately $105,000. Creative Planning bought a new stake in shares of Leap Therapeutics during the 2nd quarter valued at approximately $144,000. Spark Investment Management LLC bought a new stake in shares of Leap Therapeutics during the 1st quarter valued at approximately $146,000. Point72 Asset Management L.P. bought a new stake in shares of Leap Therapeutics during the 1st quarter valued at approximately $227,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Leap Therapeutics by 39,223.3% during the 1st quarter. JPMorgan Chase & Co. now owns 40,503 shares of the company’s stock valued at $336,000 after purchasing an additional 40,400 shares during the last quarter. 18.01% of the stock is currently owned by institutional investors.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.

Further Reading: How a Put Option Works

Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.